All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Venetoclax Induces Notable ORR But Short PFS in High-Risk Mantle Cell Lymphoma

April 5th 2023

Venetoclax, alone or in combination with a BTK inhibitor, improved overall response rate in patients with pretreated, high-risk mantle cell lymphoma, according to findings from a retrospective study. However, the BCL-2 inhibitor was associated with short durations of progression-free survival.

Novel CDK9 Inhibitor Under Investigation in Solid Tumors and NHL

April 5th 2023

Miguel Villalona-Calero, MD, discusses the unique mechanism of action of KB-0742 and the rationale and design of a phase 1 trial investigating the safety and efficacy of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma.

Sox9 Protein Enables Molecular Time Travel That Can Lead to Colorectal Cancer

April 5th 2023

Research from Dana-Farber Cancer Institute looks at what happens before the emergence of mutations that interrupt cellular differentiation in colorectal cancer and finds not only evidence of fetal reprogramming that can initiate cancer, but also a protein, Sox9, that fuels that reprogramming.

FDA Accepts BLA for Trastuzumab Biosimilar in HER2+ Breast Cancer, Gastric/GEJ Cancer

April 5th 2023

The FDA has accepted a biologics license application for the HLX02, a proposed trastuzumab biosimilar, as adjuvant therapy for patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic breast cancer, and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma

Durvalumab Regimen With Maintenance Olaparib Combo Improves PFS in Select High-Grade Epithelial Ovarian Cancer

April 5th 2023

Induction therapy with durvalumab plus chemotherapy and bevacizumab, followed by maintenance with olaparib plus durvalumab and bevacizumab, elicited a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy plus bevacizumab in patients with newly diagnosed advanced high-grade epithelial ovarian cancer who did not harbor BRCA mutations.

Not All Stage I and II Endometrial Cancers Are Alike

April 5th 2023

A recent retrospective study found that patients with endometrial cancer in International FICO stage I high- intermediate risk subgroups with fewer than 2 risk factors had a greater than 95% cause-specific survival at 3-year follow-up, and subgroups with 2 or more risk factors had poorer outcomes.

Investigators Turn a Focused Eye to Targeting Weaknesses in BPDCN

April 5th 2023

Because of the disease’s rarity relative to other hematologic malignancies and challenges arriving at an accurate diagnosis, patients with blastic plasmacytoid dendritic cell neoplasm have historically encountered a dearth of effective treatment options.

Adagrasib Induces 68% ORR in Subset of Patients With KRAS G12C–Mutated NSCLC

April 4th 2023

Adagrasib induced high overall response rates in patients with KRAS G12C–mutated non–small cell lung cancer who achieved at least 90% mutation allele frequency clearance.

Atezolizumab Following Neoadjuvant Atezolizumab and Resection Improves DFS in NSCLC

April 4th 2023

Data for adjuvant atezolizumab following neoadjuvant atezolizumab and resection demonstrated an improvement in disease-free survival and a trend toward improved overall survival in patients with resectable stage IB to IIIB non–small cell lung cancer compared with those who did not receive adjuvant atezolizumab.

American Society of Clinical Oncology Recognizes Dr Neeraj Agarwal

April 4th 2023

Neeraj Agarwal, MD, is now a distinguished member of the Fellows of the American Society of Clinical Oncology.

Dr. Sadai on Signs and Symptoms of High-Grade Meningiomas

April 4th 2023

Nader Sanai, MD, discusses symptoms associated with high-grade meningiomas, a rare brain tumor.

Dr. Brastianos on Recent Data in High-Grade Meningiomas

April 4th 2023

Priscilla K. Brastianos, MD, reviews recent findings in high-grade meningiomas, including data generated in her laboratory.

TAVO-EP Plus Pembrolizumab Fails to Meet ORR End Point in Anti–PD-1–Refractory Advanced Melanoma

April 4th 2023

The combination of the interleukin-12 encoding plasmid TAVO™-EP plus pembrolizumab did not meet the prespecified primary end point for overall response rate in patients with advanced melanoma that was refractory to anti–PD-1 therapy.

FDA Accepts sNDAs for Encorafenib and Binimetinib in BRAF V600E–Mutant NSCLC

April 4th 2023

The FDA has accepted for review supplemental new drug applications for the combination of encorafenib and binimetinib for the treatment of patients with metastatic non–small cell lung cancer harboring a BRAF V600E mutation, as detected by an FDA-approved test.

Imetelstat Displays Early Efficacy in Myelofibrosis; Phase 3 Trial Is Underway

April 4th 2023

The first-in-class telomerase inhibitor imetelstat is poised to expand the myelofibrosis treatment armamentarium should it prove safe and effective in the newly initiated phase 3 IMpactMF trial.

Teclistamab Leads Ongoing Emergence of Bispecific Antibodies in Multiple Myeloma

April 4th 2023

Jeffrey Zonder, MD, discussed the ongoing development of other BCMA-targeted and non–BCMA targeted bispecific antibodies, toxicity management for these agents, how to navigate treatment decisions for patients eligible for CAR T-cell therapy, and ongoing research in multiple myeloma at the Barbara Ann Karmanos Cancer Institute.

FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

April 3rd 2023

The FDA has granted accelerated approval to enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.

Quizartinib May Represent an Additional Therapeutic Option for FLT3-ITD+ AML

April 3rd 2023

Mark Levis, MD, PhD, discusses potential changes to the FLT3-ITD-mutated acute myeloid leukemia treatment landscape that may occur if the FDA approves quizartinib, key efficacy and safety data with the agent, and how quizartinib compares with midostaurin.

Tamibarotene Combinations Under Investigation in Newly Diagnosed AML and MDS

April 3rd 2023

Gautam Borthakur, MD, discussed the rationale for targeting RARA-overexpressing AML, the potential efficacy and safety benefits of tamibarotene, and how SELECT AML-1 and SELECT MDS-1 could change the respective treatment landscapes in AML and MDS.

Eftilagimod Alpha/Pembrolizumab Generates Antitumor Activity in PD-1–Resistant NSCLC

April 3rd 2023

Treatment with eftilagimod alpha plus pembrolizumab resulted in tumor shrinkage and a tolerable safety profile in patients with anti–PD-1/PD-L1–resistant non–small cell lung cancer.